Oruka Therapeutics (ORKA) Price & Analysis

Compare

743 Followers

ORKA Stock Chart & Stats

$34.23

-$0.35(-1.84%)

At close: Jan 08 4:00 PM EST

$34.23

-$0.35(-1.84%)

Day’s Range― - ―

52-Week Range$5.49 - $36.51

Previous CloseN/A

Volume71.58K

Average Volume (3M)530.53K

Market Cap

$1.66B

Enterprise Value$1.19B

Total Cash (Recent Filing)$349.15M

Total Debt (Recent Filing)$1.91M

Price to Earnings (P/E)―

Beta0.80

Next Earnings

Mar 05, 2026

EPS Estimate

-0.63

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.55

Shares Outstanding48,409,233

10 Day Avg. Volume602,310

30 Day Avg. Volume530,527

Financial Highlights & Ratios

PEG Ratio-0.31

Price to Book (P/B)0.85

Price to Sales (P/S)0.00

P/FCF Ratio-5.61

Enterprise Value/Market Cap0.72

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-10.53

Forecast

1Y Price Target

$57.80

Price Target Upside68.86% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Development Momentum And Market OpportunityProgression into planned Phase 2 programs in psoriasis and hidradenitis suppurativa, coupled with favorable readthrough from successful IL-17A/F drugs, points to a clear commercial pathway into a large validated market.

Dosing AdvantageExtended half-lives observed for ORKA-001 and ORKA-002 support potential for less frequent dosing than current therapies, which could improve patient adherence and competitive differentiation.

Safety ProfilePhase 1 findings showed no serious or severe treatment-emergent adverse events and no cases of oral candidiasis, suggesting a favorable safety profile that may ease regulatory scrutiny and physician acceptance.

Bears Say

Cash RunwayA limited cash runway increases the risk of near-term financing needs, which could constrain operations or delay clinical programs.

Dilution RiskPotential future equity raises to fund development could dilute existing shareholders and reduce per-share upside from clinical milestones.

Market SentimentSignificant short interest signals investor skepticism that may amplify share price volatility around clinical updates or financing events.

Oruka Therapeutics News

Oruka Therapeutics price target raised to $45 from $42 at Wedbush

Wedbush raised the firm’s price target on Oruka Therapeutics (ORKA) to $45 from $42 and keeps an Outperform...

20d ago

ORKA

Oruka Therapeutics price target raised to $71 from $46 at Clear Street

Clear Street raised the firm’s price target on Oruka Therapeutics (ORKA) to $71 from $46 and keeps a...

20d ago

ORKA

Oruka provides updates on Phase 1 trial of ORKA-002, EVERLAST-B ORKA-001 trial

Oruka Therapeutics (ORKA) announced positive interim data from its Phase 1 trial of ORKA-002 and updates from the...

21d ago

ORKA

Oruka Therapeutics initiated with a Buy at UBS

UBS initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $50 price target as the analyst...

26d ago

ORKA

Oruka Therapeutics: Long-Acting IL-17 Platform Drives Upgraded Valuation and Buy Rating

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics and increased the price target...

20d ago

ORKA

ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors

Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. Study Overview Oruka Therapeutics, Inc. is...

2M ago

ORKA

Oruka Therapeutics initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Oruka Therapeutics (ORKA) with an Overweight rating and $75 price target The firm...

2M ago

ORKA

Oruka Therapeutics Appoints Christopher Martin to Board

An announcement from Oruka Therapeutics ( ($ORKA) ) is now available. On December 11, 2025, Oruka Therapeutics, Inc....

2M ago

ORKA

Oruka Therapeutics Reports Q3 2025 Financial Results

Oruka Therapeutics, Inc. ( ($ORKA) ) has released its Q3 earnings. Here is a breakdown of the information...

3M ago

ORKA

Oruka Therapeutics price target raised to $63 from $56 at BTIG

BTIG analyst Julian Harrison raised the firm’s price target on Oruka Therapeutics (ORKA) to $63 from $56 and...

3M ago

ORKA

Oruka Therapeutics initiated with a Buy at Jefferies

Jefferies analyst Roger Song initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $45 price target...

3M ago

ORKA

Oruka Therapeutics: Promising Advancements in Monoclonal Antibodies Drive Buy Rating

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ORKA stock, giving a Buy rating...

3M ago

ORKA

Oruka Therapeutics reports Q3 EPS (55c), consensus (52c)

“We had a very successful quarter where we released our first clinical data as a company and extended...

3M ago

ORKA

ORKA Earnings this Week: How Will it Perform?

Oruka Therapeutics, Inc. (ORKA) is scheduled to report 3rd quarter earnings on 11/12/2025. Regarding Q3 estimates, Wall Street...

3M ago

ORKA

ORKA FAQ

What was Oruka Therapeutics’s price range in the past 12 months?

Oruka Therapeutics lowest stock price was $5.49 and its highest was $36.51 in the past 12 months.

What is Oruka Therapeutics’s market cap?

Oruka Therapeutics’s market cap is $1.66B.

When is Oruka Therapeutics’s upcoming earnings report date?

Oruka Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 31 days.

How were Oruka Therapeutics’s earnings last quarter?

Oruka Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.577 by $0.027.

Is Oruka Therapeutics overvalued?

According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oruka Therapeutics pay dividends?

Oruka Therapeutics pays a Notavailable dividend of $19.356 which represents an annual dividend yield of N/A. See more information on Oruka Therapeutics dividends here

What is Oruka Therapeutics’s EPS estimate?

Oruka Therapeutics’s EPS estimate is -0.63.

How many shares outstanding does Oruka Therapeutics have?

Oruka Therapeutics has 48,409,233 shares outstanding.

What happened to Oruka Therapeutics’s price movement after its last earnings report?

Oruka Therapeutics reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.577. Following the earnings report the stock price went down -6.784%.

Which hedge fund is a major shareholder of Oruka Therapeutics?

Currently, no hedge funds are holding shares in ORKA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oruka Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-23.05%

Trailing 12-Months

Asset Growth

956.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oruka Therapeutics

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics (ORKA) Earnings & Revenues

Historic Earnings Reports

ORKA Stock 12 Month Forecast

Average Price Target

$57.80

▲(68.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","25":"$25","42":"$42","59":"$59","76":"$76"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$57.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,25,42,59,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.31,33.747692307692304,37.18538461538461,40.62307692307692,44.060769230769225,47.49846153846154,50.93615384615384,54.373846153846145,57.81153846153846,61.24923076923076,64.68692307692308,68.12461538461538,71.56230769230768,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.31,32.424615384615386,34.53923076923077,36.65384615384615,38.76846153846154,40.88307692307692,42.997692307692304,45.112307692307695,47.22692307692307,49.34153846153846,51.45615384615384,53.57076923076923,55.68538461538461,{"y":57.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.31,31.055384615384614,31.80076923076923,32.54615384615384,33.29153846153846,34.036923076923074,34.78230769230769,35.527692307692305,36.27307692307692,37.01846153846154,37.76384615384615,38.50923076923077,39.254615384615384,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.39,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.17,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.67,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >